MedTrace Logo

Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers

NCT03835013 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-04-03

No results posted yet for this study

Summary

The study seeks to explore the cardiovascular effects of co-agonism at two peptide receptors, GLP-1 and glucagon. Glucagon, exenatide and 0.9% saline will be intravenously infused, both in isolation, and combination into healthy male participants. Overall, the aim of the study is to further our understanding on the role these endogenous substances play (both in isolation and combination) in haemodynamic regulation.

Conditions

Interventions

DRUG

Saline 0.9%

Intravenous infusion of 0.9% saline

DRUG

Glucagon (25ng/kg/min)

Intravenous infusion of glucagon 25ng/kg/min

DRUG

Glucagon (50ng/kg/min)

Intravenous infusion of glucagon 50ng/kg/min

DRUG

Exenatide

Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes

Sponsors & Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Ian Wilkinson, MA DM FRCP · University of Cambridge

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-11
Primary Completion
2021-11-01
Completion
2021-11-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03835013 on ClinicalTrials.gov